What Are Wall Street’s Thoughts On Selecta Biosciences Inc. Shares (SELB)?

The stock of Selecta Biosciences Inc. (NASDAQ:SELB) decreased by -$0.02 on Monday to $0.78, down -2.12 percent. The last five days have seen an average of 1,597,474 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$2.5000. The average number of shares traded over the last 20 days was 1,603,758, while the average volume over the last 50 days totaled 1,506,479.

SELB stock dropped -6.27% since last month. On 05/11/22, the company’s shares reached a one-month low of $0.6469. The stock touched a high of $5.28 on 01/03/22, after rallying from a low of $0.65 in 52 weeks. The price of SELB stock has declined by -75.59% or -$2.5000 this year, reaching a new high 1 time. Still, the stock price is down -85.25% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Insider Transactions

There have been 14 days since Selecta Biosciences Inc. (SELB) last reported insider trading activity on May 09. On May 09, Director BARABE TIMOTHY C acquired 50,000 shares at $0.77 each. This transaction resulted in the insider spending $38,720. On Jan 05, Kishimoto Takashi Kei sold 3,416 shares at a price of US$3.09. After the transaction, the insider now owns 268,353 shares. Chief Medical Officer TRABER PETER G had earlier sold 3,226 shares on Jan 05 for $3.09 a share. The transaction was completed for $9,955.

Valuation Metrics

Selecta Biosciences Inc. (SELB) has a trailing price-to-earnings (P/E) ratio of 3.75. Beta for the stock is 1.30. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.09, the price-to-book (PB) ratio of 1.77.

Financial Health

For the three months ended March 30, Selecta Biosciences Inc.’s quick ratio was 3.30, while its current ratio was 3.30, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 0.45, and the total debt to equity ratio is 0.46. Selecta Biosciences Inc.’s operating margin stood at 12.30% for the same period. Based on annual data, it had gross profit of $89.67 million and revenue of $85.08 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SELB’s return on assets (ROA) during the last 12 months has been 17.00%. There was a -42.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 200.20%.

Earnings Surprise

According to Selecta Biosciences Inc.’s quarterly financial report for the quarter that ended March 30, it had $25.04 million in total debt versus $4.0 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $34.0 million, while revenues rose by 67.5% to $29.94 million. It was predicted that Selecta Biosciences Inc.’s quarterly earnings would be $0.23, but it ended up being -$0.11, beating the consensus by 309.10%. EBITDA was $11.12 million for the quarter. At the end of Selecta Biosciences Inc.’s most recent quarter ended March 30, its liabilities totaled 89.93 million, while its total debt was $35.28 million. Equity owned by shareholders amounts to $151.81 million.

Technical Picture

Here’s a quick look at Selecta Biosciences Inc.’s (SELB) price momentum from a technical perspective. As of 20 May, the RSI 9-day stood at 44.44%, suggesting the stock is Neutral, with a 141.11% historical volatility rate.

The stochastic %K and %D were 55.70% and 57.41% respectively, while the average true range (ATR) was 0.0903. Based on the 14-day stochastic reading of 48.52%, the RSI (14) reading is 41.25%. On the 9-day MACD Oscillator, the stock is at 0.0218.

Analyst Ratings

In its analyst report released on June 15, 2021, BTIG Research began covering Selecta Biosciences Inc. (NASDAQ: SELB). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Selecta Biosciences Inc. (SELB) an Buy rating. SELB is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.

What is SELB’s price target for the next 12 months?

The current consensus forecast for the stock is between $6.00 and $13.00, with a median target price of $8.00. In analyzing these forecasts, the average price target given by analysts for Selecta Biosciences Inc. (SELB) is $8.20.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam